Major Therapeutic and Molecular Advances in MDS

Major Therapeutic and Molecular Advances in MDS 

Date: Friday, December 6, 2013
Time: 7:00 am Breakfast & Registration
7:30 – 11:00 am Presentation

Venue: Hilton New Orleans Riverside
Grand Salon C
#2 Poydras Street
New Orleans, LA 70130

blue claimcredit


Activity Overview

Target Audience:
This activity is intended for physicians, oncology nurses, nurse practitioners, physician assistants, pharmacists and other health care professionals interested in the treatment and management of patients with Myelodysplastic Syndromes. 

Learning Objectives:
Upon completion of this course, the participant will be better able to: 

  • Describe the clinical and biologic features which are useful for classifying MDS and aid in therapeutic decision-making;
  • Explain the current therapeutic options for MDS patients whose disease has not responded to standard therapy;
  • Review the current status of treatments aimed at improving severe thrombocytopenia in MDS patients;
  • Discuss how the use of flow cytometry aids diagnosing and assessing prognosis of MDS patients;
  • Identify the impact of microenvironmental abnormalities on hematopoiesis in MDS;
  • Outline pathogenetic molecular features contributing to MDS progression.

Commercial Support:
Supported by educational grants from: Amgen, Baxter, Celgene, Novartis and Onconova.

Amgen Logo - Blue with tagline preferred one to use Baxter logo Celgene Novartis - NO Oncology OnconovaLogoTagLine

Recent developments in clinical, immunophenotypic, and molecular risk analyses have generated major advances for aiding management of patients with myelodysplastic syndromes (MDS). These methods and current therapies, with novel agents and their combinations, will be discussed. Also discussed will be the biologic implications of marrow cell molecular mutations and microenvironmental abnormalities for improving the understanding of pathogenetic lesions underlying this disease. 

Criteria for Success
Statements of credit will be awarded based on the participant's attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at If you have questions about this CME/CE activity, please contact AKH Inc. at This email address is being protected from spambots. You need JavaScript enabled to view it. .


mds-logo-small     AKH-Logo-No-background2 


Benjamin Ebert, MD, PhD
Associate Professor of Medicine
Brigham and Women's Hospital
Harvard Medical School
Boston, MA

Pierre Fenaux, MD
Professor of Hematology 
Hôpital St Louis 
Paris 7 University
Paris, France

Peter Greenberg, MD
Professor of Medicine
Stanford University Cancer Center 
Stanford, CA

David Scadden, MD
Gerald and Darlene Jordan Professor of Medicine
Harvard University
Cambridge, MA

Arjan van de Loosdrecht, MD, PhD
Professor of Hematology
VU University Medical Center
Amsterdam, The Netherlands



AKH-Logo-No-background2CME/CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and MDS Foundation.  AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.   AKH Inc. designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credit(s)™.  Physicians should claim only credit commensurate with the extent of their participation in the activity.

Physician Assistants 
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

AKH Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. AKH Inc. approves this knowledge- based activity for 3.5 contact hour(s) (0.35 CEUs). UAN 0077-9999-13-021-L04-P.

AKH Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s COA. 
AKH Inc. designates this educational activity for 3.5 contact hours.  Accreditation applies solely to educational activities and does not imply approval or endorsement of any commercial product by the ANCC-COA.